IL112428A - Pharmaceutical compositions comprising an oligosaccharide sequence which bind toxin a of clostridium difficile - Google Patents

Pharmaceutical compositions comprising an oligosaccharide sequence which bind toxin a of clostridium difficile

Info

Publication number
IL112428A
IL112428A IL11242895A IL11242895A IL112428A IL 112428 A IL112428 A IL 112428A IL 11242895 A IL11242895 A IL 11242895A IL 11242895 A IL11242895 A IL 11242895A IL 112428 A IL112428 A IL 112428A
Authority
IL
Israel
Prior art keywords
clostridium difficile
pharmaceutical compositions
oligosaccharide sequence
bind toxin
bind
Prior art date
Application number
IL11242895A
Other languages
English (en)
Other versions
IL112428A0 (en
Original Assignee
Synsorb Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synsorb Biotech Inc filed Critical Synsorb Biotech Inc
Publication of IL112428A0 publication Critical patent/IL112428A0/xx
Publication of IL112428A publication Critical patent/IL112428A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL11242895A 1994-02-14 1995-01-24 Pharmaceutical compositions comprising an oligosaccharide sequence which bind toxin a of clostridium difficile IL112428A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/195,009 US5484773A (en) 1994-02-14 1994-02-14 Treatment of antibiotic associated diarrhea

Publications (2)

Publication Number Publication Date
IL112428A0 IL112428A0 (en) 1995-03-30
IL112428A true IL112428A (en) 1999-08-17

Family

ID=22719705

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11242895A IL112428A (en) 1994-02-14 1995-01-24 Pharmaceutical compositions comprising an oligosaccharide sequence which bind toxin a of clostridium difficile

Country Status (15)

Country Link
US (2) US5484773A (xx)
EP (1) EP0744959B1 (xx)
JP (1) JP4122052B2 (xx)
KR (1) KR970701064A (xx)
CN (1) CN1131070C (xx)
AT (1) ATE267614T1 (xx)
AU (1) AU698275B2 (xx)
CA (1) CA2181359C (xx)
DE (1) DE69533084T2 (xx)
IL (1) IL112428A (xx)
MX (1) MX197129B (xx)
NO (1) NO963378D0 (xx)
NZ (1) NZ279180A (xx)
WO (1) WO1995021628A1 (xx)
ZA (1) ZA95630B (xx)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2150888T1 (es) * 1991-10-18 2000-12-16 Synsorb Biotech Inc Diagnosis y tratamiento de la disenteria bacteriana.
DE4428056A1 (de) * 1994-07-29 1996-02-08 Schering Ag Verwendung von Mikropartikelpräparationen zur Eliminierung gelöster, nicht nierengängiger Substanzen aus dem Blut
US6140045A (en) * 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
US5661131A (en) * 1995-06-05 1997-08-26 Synsorb Biotech, Inc. Treatment of cholera
US5627163A (en) * 1995-06-05 1997-05-06 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US5811409A (en) * 1995-06-05 1998-09-22 Synsorb Biotech, Inc. Treatment of cholera
US5637576A (en) * 1995-06-05 1997-06-10 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
US6069137A (en) * 1996-03-11 2000-05-30 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US5891860A (en) * 1996-03-11 1999-04-06 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
JPH107575A (ja) * 1996-06-21 1998-01-13 Synsorb Biotec Inc 細菌性赤痢の処置
US6013634A (en) * 1996-11-08 2000-01-11 Synsorb Biotech, Inc. Solid support matrices containing a toxin binding oligosaccharide
US5846943A (en) * 1996-11-08 1998-12-08 Synsorb Biotech, Inc. Solid support matricles containing a toxin binding oligosaccharide
US6063769A (en) * 1996-11-14 2000-05-16 Synsorb Biotech, Inc. 1-thiogalactose derivatives
US6087339A (en) * 1996-11-14 2000-07-11 Synsorb Biotech, Inc. Saccharide derivatives
US5968907A (en) * 1996-11-14 1999-10-19 Synsorb Biotech, Inc. 1-thiogalactose derivatives
US5932554A (en) * 1996-11-14 1999-08-03 Synsorb Biotech, Inc. 1-galactose derivatives
EP0938492A1 (en) * 1996-11-15 1999-09-01 SYNSORB Biotech Inc. Combinatorial synthesis of carbohydrate libraries
US5965719A (en) * 1996-11-15 1999-10-12 Sunsorb Biotech, Inc. Combinatorial synthesis of carbohydrate libraries
US6096725A (en) * 1997-07-02 2000-08-01 Neose Technologies, Inc. Methods of using αGal oligosaccharides as immune system targeting agents
US20020019991A1 (en) * 1998-04-30 2002-02-14 Abbott Laboratories Compositions containing an alpha 1,2-fucose linkage and uses thereof
US6174867B1 (en) 1998-05-08 2001-01-16 Synsorb Biotech, Inc. 1-galactose derivatives having a carbon- or nitrogen-containing aglycon linkage
US6358930B1 (en) * 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
US6013635A (en) * 1998-05-28 2000-01-11 Synsorb Biotech, Inc. Treatment of C. difficile toxin B associated conditions
US6291435B1 (en) * 1999-03-04 2001-09-18 The Governs Of The University Of Alberta Treatment of diarrhea caused by enteropathogenic Escherichia coli
US6270755B1 (en) 1999-05-13 2001-08-07 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders
US6290946B1 (en) * 1999-05-13 2001-09-18 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders and antibacterial agents
CA2314494A1 (en) 2000-05-02 2001-11-02 Geltex Pharmaceuticals, Inc. Anionic polymers as species specific antibacterial agents
US6596707B2 (en) * 2001-05-24 2003-07-22 Abbott Laboratories Monovalent saccharides and uses thereof
KR20050030208A (ko) * 2002-07-22 2005-03-29 젠자임 코포레이션 폴리(칼륨 및 나트륨 스티렌 설포네이트), 이의 제조방법및 용도
US7682631B2 (en) * 2003-10-01 2010-03-23 Clemson University Adhesin-specific nanoparticles and process for using same
US7893041B2 (en) * 2003-12-05 2011-02-22 Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
US20060078534A1 (en) * 2004-10-13 2006-04-13 Dominique Charmot Toxin binding compositions
WO2006044577A1 (en) * 2004-10-13 2006-04-27 Ilypsa, Inc. Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
CA2608505C (en) * 2005-05-18 2013-12-24 Da Volterra Colonic delivery of adsorbents
US7915235B2 (en) * 2006-03-20 2011-03-29 Brian Dieckgraefe High affinity ligands bind to clostridium difficile toxin A
WO2007114683A1 (en) * 2006-03-30 2007-10-11 N.V. Nutricia Milk oligosaccharides for stimulating the immune system
US8048413B2 (en) * 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US20080041643A1 (en) * 2006-08-17 2008-02-21 Khalife Tony N Wind-power vehicle aka WPV
EP2185931B1 (en) 2007-09-07 2013-07-10 Children's Hospital Medical Center Use of secretor, lewis and sialyl antigen levels as predictors for disease
EP2451462B1 (en) 2009-07-06 2017-09-06 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
US10857167B2 (en) 2015-04-28 2020-12-08 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
CN108977497A (zh) * 2018-06-12 2018-12-11 深圳市领治医学科技有限公司 一种采集和保存人痕量粪便样本的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1544908A (en) * 1975-07-08 1979-04-25 Chembiomed Ltd Artificial oligosaccharide antigenic determinants
US4362720A (en) * 1977-04-14 1982-12-07 Chembiomed Ltd. Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2-deoxyglycosides from glycals
DE2857790C2 (de) * 1977-04-14 1983-12-22 Chembiomed Ltd., Edmonton, Alberta Verfahren zur Herstellung von O-geschützten 2-Azido-2-desoxy-glycosylhalogeniden, einige derartige Verbindungen als solche und deren Verwendung
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US4863852A (en) * 1985-07-03 1989-09-05 Virginia Tech Intellectual Properties, Inc. Method of detecting, isolating and purifying clostridium difficile toxin A and its receptors
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5098826A (en) * 1990-03-09 1992-03-24 Virginia Tech Intellectual Properties, Inc. Detection, isolation and purification of Clostridium difficile toxin A with toxin receptors
US5266315A (en) * 1990-05-07 1993-11-30 Kabushiki Kaisha Miyarisan Seibutsu Igaku Kenkyusho Composite for Clostridium difficile diarrhea and pseudomembranous colitis
ES2150888T1 (es) * 1991-10-18 2000-12-16 Synsorb Biotech Inc Diagnosis y tratamiento de la disenteria bacteriana.

Also Published As

Publication number Publication date
NO963378L (no) 1996-08-13
NZ279180A (en) 1997-10-24
US5484773A (en) 1996-01-16
ZA95630B (en) 1995-10-05
MX9603403A (es) 1998-10-31
DE69533084T2 (de) 2005-06-09
NO963378D0 (no) 1996-08-13
EP0744959A1 (en) 1996-12-04
DE69533084D1 (de) 2004-07-01
WO1995021628A1 (en) 1995-08-17
IL112428A0 (en) 1995-03-30
CN1140415A (zh) 1997-01-15
KR970701064A (en) 1997-03-17
CA2181359A1 (en) 1995-08-17
MX197129B (es) 2000-06-23
EP0744959B1 (en) 2004-05-26
CN1131070C (zh) 2003-12-17
AU1572795A (en) 1995-08-29
ATE267614T1 (de) 2004-06-15
US5635606A (en) 1997-06-03
JPH09508631A (ja) 1997-09-02
JP4122052B2 (ja) 2008-07-23
AU698275B2 (en) 1998-10-29
CA2181359C (en) 2001-07-03

Similar Documents

Publication Publication Date Title
IL112428A (en) Pharmaceutical compositions comprising an oligosaccharide sequence which bind toxin a of clostridium difficile
EP1089740B8 (en) Compositions for the treatment of cdad initiated by c. difficile toxin b
MX9701683A (es) Tratamiento terapeutico de enfermedades asociadas a clostridium difficile.
WO1995021628B1 (en) Treatment of antibiotic associated diarrhea
EP1072270A3 (en) Botulinum toxins for treating dystonia
EP0456418A3 (en) Treatment of clostridium difficile diarrhoea and pseudomembranous colitis
AU2473592A (en) Detergent compositions containing lipase and terpene
AU2613995A (en) Lactobacillus strains of human origin, their compositions and uses thereof
TR200201744T2 (tr) Bitki hastalıklarının kontrol edilmesi için bacillus pumilus soyu
IL127581A0 (en) Crystal form i of clarithromycin
EP0828481A4 (en) ORAL DELIVERY COMPOSITION FOR INTESTINAL RELEASE AND METHOD OF USE
BG101131A (en) 2-oxo-and 2-thio-1,2-dihydroquinolinyl-oxazolidinons
AU8812498A (en) Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
ZA965731B (en) Clostridium difficile toxins as mucosal adjuvants.
WO2001032219A3 (en) Treatment of c. difficile toxin b associated conditions
HU910705D0 (en) Medical preparation
NZ217679A (en) Antibiotic fermentates from kibdelosporangium aridum largum and compositions
GB9401447D0 (en) Pharmaceutical compositions
GB8928811D0 (en) An activator for damaged neurocytes for the prevention and treatment of disease
EP0634168A4 (xx)
MX9802809A (es) Ureasa para el tratamiento de infecciones de helicobacter pylori.
MX9803694A (es) Derivados de 3-desoxi-3-desclandinosa de eritromicinas a y b.
TW346397B (en) Cell cycle controlling compositions and methods of using same
MX9705119A (es) Interferona modificada quimicamente.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed